

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Market Research Report | 2024-01-22 | 492 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies. The markets for NGS-based diagnostics are given for the years 2020, 2021, 2022, 2023 and 2028.

This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed.

The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.

The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health, and transplant medicine.

Specific geographic markets are discussed, namely North America, Europe, Asia-Pacific, and the Rest of the World.

Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct-to-consumer testing; and noninvasive prenatal

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

testing.

More than 100 companies in the clinical NGS industry are profiled in this report.

BCC Research also provides a summary of the recent, primary industry acquisitions and strategic alliances, including key alliance trends.

Report Includes:

- 41 data tables and 237 additional tables
- An overview of the global market for emerging clinical applications of next-generation sequencing
- Analysis of global market trends, featuring historical revenue data for 2020 to 2022, estimates for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by disease indication, test complexity, test purpose, application and geographic region
- Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenarios and use of NGS-based diagnostics and technologies
- Coverage of genome mapping programs, technological advances and innovations in NGS platforms, and the Ion Torrent Genexus System from Thermo Fisher Scientific and the Magnis NGS Prep System from Agilent Technologies Inc
- Description of NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT), and a discussion of their advantages
- Market share analysis of the key companies and a look at their proprietary technologies, strategic alliances and other key market strategies, plus a patent analysis
- Profiles of the leading players, including Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN, Agilent Technologies Inc., and BGI Genomics

Executive Summary

Summary:

Since NGS platforms can sequence an entire genomic region or even an entire genome, a single test can examine hundreds or thousands of clinically important genetic variations. This means that one test can replace multiple conventional single-gene tests, providing an advantage in price and in the amount of precious sample needed for the test itself.

NGS is often more accurate and reliable than existing diagnostics. This can result in better clinical outcomes. For example, NGS can increase the pregnancy success rates in in vitro fertilization applications. Also, in rare genetic diseases, NGS can increase the success rates for determining a molecular diagnosis.

The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test. This strategy has been employed in reproductive health applications, for example, launching a test to initially screen for aneuploidies, and then later expanding the test to include screening for additional genetic variants.

These features of NGS platforms provide a solid basis for the use of this technology in the clinic.

Table of Contents:

Table of Contents

Chapter 1 Introduction

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
What's New in This Report?
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Market Summary
Chapter 3 Overview
Introduction
Liquid and Tissue Biopsy
Clinical NGS Market
Growth Drivers of Clinical NGS
Key Trends
Industry
Chapter 4 Technology Background
Importance of DNA
Genetic Variation and Analysis
Genetic Analysis Technologies
Sequencing in Clinical Applications
Sequencing Technologies
History of DNA Sequencing
Sanger Sequencing Technology
NGS Platforms
Short-Read Platforms
Long-Read Platforms
Informatics Technologies
Base Calling
Mapping to a Reference Sequence
Variant Analysis
Artificial Intelligence Technologies
Clinical Sequencing Technology Challenges
Chapter 5 Clinical NGS Initiatives and Emerging Technologies
R&D Initiatives and Programs
1+ Million Genomes
Access to Treatment and Testing (ACTT)
Access to Comprehensive Genomic Profiling Coalition (ACGP)
Africa Pathogen Genomics Initiative
Blood Profiling Atlas
Cancer-ID
Cancer Moon Shots Program
China Precision Medicine Initiative
ClinGen
CTC Trap Consortium

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

diaRNAgnosis Project
Early Cancer Detection Consortium
EpiFemCare
France Genomic Medicine Plan
Friends of Cancer Research Project
Genomic Medicine Sweden
HCA-Organoid
Human Cell Atlas
Human Immunomics Initiative
Immunomonitor Consortium
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program
Intervene
Liquid Biopsies and Imaging for Improved Cancer Care
Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project
Liver Cancer Early Screening Comprehensive Prevention and Control Project
Lung Cancer Genomic Screening Project for Individualized Medicine in Asia
Million Veteran Program
Medical Genome Initiative
MedSeq
Precision Medicine Initiative
Prompt
QuIP Project
SPHERES
Target ALS Diagnosis Initiative
TopMed
Treehouse Childhood Cancer Initiative
Very Rare Cancer Consortium
Worldwide Innovative Networking (WIN) Consortium
Single-Cell Research
Cambridge Single-Cell Analysis Core Facility
Harvard Medical School Single-Cell Core
Mayo Medical Genome Facility
National Center for Single-Cell Biology
Next-Generation Single-Cell Analysis Program
Single-Cell Analysis Core
UC San Francisco Single-Cell Analysis Center
The Wistar Institute of Anatomy and Biology
Population Sequencing Projects
Chapter 6 Clinical NGS Applications
Introduction
Cancer Applications
Precision Medicine
Liquid Biopsy Biomarkers
Mendelian Disorders Applications
Reproductive Health Applications
Noninvasive Prenatal Testing
Newborn Screening

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Microbiology and Infectious Disease Applications
Complex Disorders Applications
Chapter 7 Clinical NGS Industry
Sequencing Instrument Industry
Companies
Third-Generation Sequencing Industry
Sequencing Informatics Industry
Target Enrichment and Amplification Industry
CTC Capture and Detection Industry
Liquid Biopsy Assay Industry
Liquid Biopsy Cancer Screening/Early Detection Industry
Health-Focused DTC Genetic Testing Industry: Two Market Models
DTC Clinical Health Genetic Testing Industry
Noninvasive Prenatal Testing (NIPT) Industry
Chapter 8 ESG Development
Introduction to ESG
The Sustainability of NGS in Industry
Case Study
BCC Research Viewpoint
Chapter 9 Acquisitions and Strategic Alliances
Acquisitions
Strategic Alliances
Key Trends
Chapter 10 Clinical NGS Markets
Market Dynamics
Market Drivers
Impact of COVID-19 on the Clinical NGS Markets
Clinical NGS Market by Disease Category
Clinical NGS Market by Test Complexity
Clinical NGS Market by Purpose of Test
Clinical NGS Market in Oncology
Market by Indication in Oncology
NGS Market in Oncology by Purpose of Test
NGS Market in Oncology by Test Complexity
Clinical NGS Market in Cardiology
NGS Market in Cardiology by Purpose of Test
NGS Market in Cardiology by Test Complexity
Clinical NGS Market in Mendelian Disorders
NGS Market in Mendelian Disorders by Test Complexity
Clinical NGS Market in Metabolic/Immune Disorders
NGS Market in Metabolic/Immune Disorders by Purpose of Test
NGS Market in Metabolic/Immune Disorders by Test Complexity
Clinical NGS Market in Neurology
NGS Market in Neurology by Test Purpose
NGS Market in Neurology by Test Complexity
Clinical NGS Market in Reproductive Health
Reproductive Health Market by Test Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

NGS Market in Reproductive Health by Purpose of Test
NGS Market in Reproductive Health by Test Complexity
Clinical NGS Market in Microbiology and Infectious Diseases
NGS Market in Microbiology and Infectious Diseases by Purpose of Test
NGS Market in Microbiology and Infectious Diseases by Test Complexity
Clinical NGS Market in Transplantation
NGS Market in Transplantation by Organ Type
NGS Market in Transplantation by Purpose of Test
NGS Market in Transplantation by Test Complexity
Clinical NGS Market by Region
Global Market for NGS in Oncology by Region
Global Market for NGS in Reproductive Health by Region
Global Market for NGS in Transplantation by Region
Chapter 11 Patent Review
Patents on Circulating Tumor Cells
Patents on Exosomes
Patents on Cell-Free DNA
Patents Related to Biomarkers
Patent Considerations for the Use of Artificial Intelligence in Cancer Diagnostics
Liquid Biopsy Patent Litigation
Chapter 12 Company Profiles
Competitive Landscape
Top 5 Companies
AGILENT TECHNOLOGIES INC.
BGI GENOMICS CO. LTD
ILLUMINA INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
Other Companies
ACCURAGEN HOLDINGS
ADAPTIVE BIOTECHNOLOGIES
ALCEN
AMBRY GENETICS
AMOY DIAGNOSTICS CO. LTD.
ANGLE PLC
APOSTLE SCIENCES
ARCEDI BIOTECH APS
ARMONICA TECHNOLOGIES INC.
ARUP LABORATORIES
ASURAGEN INC.
BAYLOR GENETICS
BECTON, DICKINSON AND CO.
BERRY GENOMICS BEIJING
BIOCAPTIVA LTD.
BIOCEPT INC.
BIODESIX
BIOFLUIDICA

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

BIOLIDICS LTD
BIOLOGICAL DYNAMICS
BIOMODAL
BIONANO GENOMICS
BIO-RAD LABORATORIES INC.
BIO-TECHNE
C2I GENOMICS
CAPIO BIOSCIENCES
CAREDX INC.
CARIS LIFE SCIENCE
CEGAT GMBH
CELL MICROSYSTEMS
CENTRILLION GENOMICS TECHNOLOGIES
CLARET BIOSCIENCE
CLEAR NOTE HEALTH
CLINICAL GENOMICS TECHNOLOGIES
CYCLOMICS
CYGNUS BIOSCIENCES CO. LTD.
DANAHER
DANTE LABS
DATAR CANCER GENETICS LTD.
DELFI DIAGNOSTICS
DIACARTA
DIAGNOLOGIX LLC
DIAGNOMICS INC.
DIAMIR BIO
DNALYTICS
DNANEXUS INC.
EARLYDIAGNOSTICS
EONE-DIAGNOMICS GENOME CENTER CO. LTD.
EPIC SCIENCES
EPIGENOMICS AG
EUROFINS GENOMICS
EVERLY HEALTH INC.
EXACT SCIENCES CORP.
EXOPERT
EXOSOMICS INC.
EZLIFE BIO
FABRIC GENOMICS INC.
F. HOFFMANN-LA ROCHE LTD
FLUXION BIOSCIENCES INC.
FREENOME HOLDINGS INC.
FULGENT GENETICS
FULL GENOMES CORP.
GENE BY GENE LTD.
GENEDX LLC
GENESEQ BIOSCIENCES

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

GENOMONCOLOGY LLC
GENOSABER
GRAIL INC.
GUARDANT HEALTH
HELIO GENOMICS
HELIX INC.
HTG MOLECULAR DIAGNOSTICS INC.
IMAGIA CANEXIA HEALTH
INCELLDX INC.
INEX INNOVATE PRIVATE LTD
INOVIQ
INTERPACE BIOSCIENCES INC.
INVITAE CORP.
INVIVOSCRIBE INC.
JABREHOO MED TECH CO. LTD.
JBS SCIENCE
JUMPCODE GENOMICS INC.
KONINKLIJKE PHILIPS N.V.
LABGENOMICS CO. LTD.
LABORATORY CORPORATION OF AMERICA HOLDINGS
LIQUID BIOPSY LABS
LUCENCE HEALTH INC.
LUNGLIFE AI INC.
MACROGEN INC.
MAPMYGENOME
MDXHEALTH INC.
MEDGENOME
MEDICOVER GENETICS
MENARINI SILICON BIOSYSTEMS SPA
MERCK KGAA
MICAREO RARE CELL DIAGNOSTICS
MICRONOMA INC.
MIR SCIENTIFIC
MUTANTDX
MYRIAD GENETICS INC.
NANOSTRING TECHNOLOGIES INC.
NATERA INC.
NEBULA GENOMICS
NEOGENOMICS LABORATORIES
NEW ENGLAND BIOLABS
NEW HORIZON HEALTH LTD.
NOVIGENIX SA
NOVOGENE CO. LTD.
NRICHDX INC.
NUPROBE INC.
NX PRENATAL INC.
ONCIMMUNE HOLDINGS PLC

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

ONCOCYTE CORP.
ONCODNA
OPKO HEALTH
ORCHID
OXFORD NANOPORE TECHNOLOGIES LTD.
PACIFIC BIOSCIENCES OF CALIFORNIA INC.
PANGAEA ONCOLOGY
PERSONAL GENOME DIAGNOSTICS INC.
PERSONALIS INC.
PHASE SCIENTIFIC
PIERIANDX
PREDICINE
PRENETICS GROUP
QCDX LLC
QUANTAPORE
QUANTGENE INC.
QUANTUMDX
QUEST DIAGNOSTICS
RARECELLS INC.
RAVGEN
REAL TIME GENOMICS
RESOLUTION BIOSCIENCE INC.
SAGA DIAGNOSTICS AB
SANO GENETICS
SCREENCELL
SEEKIN INC.
SEQUENCING.COM
SEVEN BRIDGES GENOMICS INC.
SINGLE TECHNOLOGIES
SMARTCATCH
STAGEZERO LIFE SCIENCES. LTD.
STRAND
STRATA ONCOLOGY
SYAPSE INC.
SYSMEX INOSTICS GMBH
TAKARA BIO INC.
TELEXOS GMBH
TWINSTRAND BIOSCIENCES INC.
TWIST BIOSCIENCE
UNCHAINED LABS
UNIVERSAL DX
VELA DIAGNOSTICS
VERACYTE
VOLITIONRX
VORTEX BIOSCIENCES
YOURGENE HEALTH
YIKON GENOMICS CO. LTD.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Market Research Report | 2024-01-22 | 492 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

